ArticleESMO gastrointestinal oncology2026
DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.
A Gordon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
ArticleESMO gastrointestinal oncology2026
A Gordon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.